MSM/4
اجتماع آلية الدول الأعضاء بشأنالمنتجات الطبية المتدنية النوعية والمغشوشة
List of Participants
A/MSM/4/1
Provisional agenda
A/MSM/4/2
Create a focal point network for the exchange of information and consultation at
large among Member States and establish an ongoing virtual exchange forum Terms
of reference for the Global Focal Point Network for
substandard/spurious/falsely-labelled/falsified/ counterfeit (SSFFC) medical
products
A/MSM/4/3
EXISTING TECHNOLOGIES AND “TRACK AND TRACE” MODELS IN USE AND TO
BE DEVELOPED BY MEMBER STATES Draft document submitted by Argentina
A/MSM/4/4
A review of WHO’s work on the issue of access to quality, safe, efficacious and
affordable medical products
A/MSM/4/5
Create a working group to develop and leverage existing recommendations for
effective risk communication and recommendations for awareness campaigns on
substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical
products and related actions, activities and behaviours Paper submitted by the
United Kingdom of Great Britain and Northern Ireland
A/MSM/4/6
A proposal for a study on the public health and socioeconomic impact of
substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical
products Economic impact study of falsified and substandard medicines Paper
submitted by the technical group established to conduct the study on the public
health and socioeconomic impact of SSFFC medical products
A/MSM/4/7
Extract from document A68/33, Annex 2
A/MSM/4/8
WHO’s participation in the global steering committee for quality assurance of
health products
A/MSM/4/9
Review of the Member State mechanism by the Health Assembly in 2017 Proposed
approach and modalities
A/MSM/4/10
Report of the fourth meeting of the Member State mechanism on
substandard/spurious/falsely-labelled/falsified/counterfeit medical products
